Clinical Trial

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

Name: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects — clinical trial record (NCT05942625)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2023-07-04; most recent amendment 2024-10-07.

Trial Details

NCT Number	NCT05942625
Lead Sponsor	Hansoh BioMedical R&D Company
Conditions	IgA Nephropathy, Focal Segmental Glomerulosclerosis
Enrollment	84 participants
Start Date	2023-05-23
Primary Completion	2024-06-30 (estimated)
Study Completion	2024-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-10-09